PHARMACOTHERAPY FOR PREMENSTRUAL DYSPHORIC DISORDER: A META-ANALYSIS OF PHASE 3 TRIALS
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient’s global function. Patients and physicians alike are often uncertain whether prescription medication for PMDD is suffi ciently effective. The primary objective of this analysis is signal detection in effi cacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confi rmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective
Abstract
Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient’s global function. Patients and physicians alike are often uncertain whether prescription medication for PMDD is suffi ciently effective. The primary objective of this analysis is signal detection in effi cacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confi rmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective
참고문헌 (17)
- Logue CM, "Perimenstrual symptoms: prevalence and risk factors", Psychosom Med, 48, pp.388~414 (1986)
- Ramcharan S, "The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors", J Clin Epidemiol, 45, pp.377~392 (1992)
- Sveinsdóttir H, "Menstrual cycle symptom variation in a community sample of women using and not using oral contraceptives", Acta Obstet Gynecol Scand, 79, pp.757~764 (2000)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th ed" (2000), American Psychiatric Association
- Wittchen HU, "Prevalence, incidence and stability of premenstrual dysphoric disorder in the community", Psychol Med, 32, pp.119~132 (2002)
- Halbreich U, "The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS", PMDD), 2003, pp.28(3), 1~23
- Freeman EW, "Premenstrual syndrome: current perspectives on treatment and etiology", Curr Opin Obstet Gynecol, 9, pp.147~153 (1997)
- Halbreich U, "Premenstrual syndromes: closing the 20th century chapters", Curr Opin Obstet Gynecol, 11, pp.265~270 (1999)
- Mortola JF., "Premenstrual syndrome", Trends Endocrinol Metab, 7, pp.184~189 (1996)
- Pearlstein TB, "Treatment of premenstrual dysphoric disorder with a new drospirenonecontaining oral contraceptive formulation", Contraception, 72, pp.414~421 (2005)
- "Clinical trials 91001" (2012)[URL]
- "Clinical study 29060/677" (2012)[URL]
- "Clinical study 29060/688" (2012)[URL]
- "Clinical study 29060/689" (2012)[URL]
- "Clinical study 29060/711" (2012)[URL]
- "Clinical study 29060/717" (2012)[URL]
- "PAXIL (paroxetine hydrochloride) tablets and oral suspension" (2012)[URL]